The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-25. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Positions of employment === 1982-1985 Instructor and assistant. Associate Professor, University of Copenhagen 1986-1987 Clinical Department Ph.D. scholarship, University of Copenhagen 1987-1988 Department of Pharmacology Ph.D. scholarship, University of Copenhagen 1988 - 1991 Pharmacologist at LEO Pharma 1991 - 2000 Management positions at Novo Nordisk, from 1994 as research director 1991 – 1993 Head of growth hormone pharmacology, Biopharmaceuticals Division, Novo Nordisk 1993 – 1994 Director of pharmacology, Diabetes Care Division, Novo Nordisk 1994 – 1995 Senior vice president of diabetes research & development, Diabetes Care Division, Novo Nordisk 1995 – 1998 Corporate vice president of Drug Discovery, Novo Nordisk 1998 – 2000 Corporate vice president of drug discovery and preclinical development, Novo Nordisk 2000 – 2021 Group vice president of research and development, Novo Nordisk 2000 – adjunct professor of pharmacology, University of Copenhagen 2021 - CEO, Novo Nordisk Foundation
2010: Marcia McNutt became the first female director of the United States Geological Survey. 2011: Kazakhstani neuroscience student and computer hacker Alexandra Elbakyan launched Sci-Hub, a website that provides users with pirated copies of scholarly scientific papers. Within five years, Sci-Hub grew to contain 60 million papers and recorded over 42 million annual downloads by users. Elbakyan was finally sued by major academic publishing company Elsevier, and Sci-Hub was subsequently taken down, but it reappeared under different domain names. 2011: Taiwanese-American astrophysicist Chung-Pei Ma led a team of scientists in discovering two of the largest black holes ever observed. 2012: Israeli-American computer scientist and cryptographer Shafi Goldwasser won the Turing award for her contributions to cryptography and complexity theory. 2013: Canadian-British genetic specialist Turi King identified the 500-year-old skeletal remains of King Richard III. 2013: Kenyan ichthyologist Dorothy Wanja Nyingi published the first guide to freshwater fish species of Kenya. 2013: Canadian teenagers Miranda Wang and Jeanny Yao jointly identify a bacteria in British Columbia's Fraser River that breaks down phthalates. 2014: Norwegian psychologist and neuroscientist May-Britt Moser received the Nobel Prize in Physiology or Medicine, shared with Edvard Moser and John O'Keefe, "for their discoveries of cells that constitute a positioning system in the brain".
==== Japan ==== In Japanese cuisine, they are called harusame (春雨), literally "spring rain". Unlike Chinese glass noodles, they are usually made from potato starch. They are commonly used to make salads, or as an ingredient in hot pot dishes. They are also often used to make Japanese adaptations of Chinese and Korean dishes. Shirataki noodles are translucent, traditional Japanese noodles made from the konjac yam and sometimes tofu.
These anatomical differences between squid and octopuses can help explain why squid can be found swimming comparably to fish while octopuses usually rely on other forms of locomotion on the sea floor such as bipedal walking, crawling, and non-jetting swimming.
=== Peptide transport === TAP-mediated peptide transport is a multistep process. The peptide-binding pocket is formed by TAP-1 and TAP-2. Association with TAP is an ATP-independent event, 'in a fast bimolecular association step, peptide binds to TAP, followed by a slow isomerisation of the TAP complex'. It is suggested that the conformational change in structure triggers ATP hydrolysis and so initiates peptide transport. Both nucleotide-binding domains (NBDs) are required for peptide translocation, as each NBD cannot hydrolyse ATP alone. The exact mechanism of transport is not known; however, findings indicate that ATP binding to TAP-1 is the initial step in the transport process, and that ATP bound to TAP-1 induces ATP binding in TAP-2. It has also been shown that undocking of the loaded MHC class I is linked to the transport cycle of TAP caused by signals from the TAP-1 subunit.
Sources: en.wikipedia.org
Nandrolone, also known as 19-nortestosterone (19-NT) or as estrenolone, as well as estra-4-en-17β-ol-3-one or 19-norandrost-4-en-17β-ol-3-one, is a naturally occurring estrane (19-norandrostane) steroid and a derivative of testosterone (androst-4-en-17β-ol-3-one). It is specifically the C19 demethylated (nor) analogue of testosterone. Nandrolone is an endogenous intermediate in the production of estradiol from testosterone via aromatase in mammals including humans and is present in the body naturally in trace amounts. It can be detected during pregnancy in women. Nandrolone esters have an ester such as decanoate or phenylpropionate attached at the C17β position.
== External links == Clinical trial number NCT04186819 for "Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)" at ClinicalTrials.gov Clinical trial number NCT04186845 for "Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)" at ClinicalTrials.gov
Socialist Studies interprets the 1988 resolution as having completely changed the party's name and proscribing the use of the full form. They see this resolution as conflicting with the party's Declaration of Principles, one clause of which mentions the party's full name explicitly. It is largely on this basis that they justified their continued operation as the Socialist Party of Great Britain, claiming that they were expelled from the Socialist Party, not the Socialist Party of Great Britain. They also claim that they are entitled to use the name because the original Socialist Party of Great Britain no longer exists: The Socialist Party of Great Britain of 52 Clapham High Street, London SW4 7UN, is defunct and no longer exists as a political party. It does not produce political literature, hold propaganda meetings or contest elections. It cannot exist merely as a name without a body. [...] We are the only political organisation in this country bearing the title 'The Socialist Party of Great Britain'. More recently, the 1988 resolution was reversed at a conference in 2008.
== Epidemiology == Fever is one of the most common medical signs. It is part of about 30% of healthcare visits by children, and occurs in up to 75% of adults who are seriously sick. About 5% of people who go to an emergency room have a fever.
Sources: en.wikipedia.org
== Limitations of MRS == The major limitation to MRS is its low available signal due to the low concentration of metabolites as compared to water. As such, it has inherently poor temporal and spatial resolution. Nevertheless, no alternate technique is able to quantify metabolism in vivo non-invasively and thus MRS remains a valuable tool for research and clinical scientists. In addition, despite recent efforts toward international expert consensus on methodological details like shimming, motion correction, spectral editing, spectroscopic neuroimaging, other advanced acquisition methods, data processing and quantification, application to brain, proton spectroscopy application to skeletal muscle, phosphorus application to skeletal muscle, methods description, results reporting, and other considerations, currently published implementations of in vivo magnetic resonance spectroscopy cluster into literatures exhibiting a broad variety of individualized acquisition, processing, quantification, and reporting techniques. This situation may contribute to a low sensitivity and specificity of, for example, in vivo proton magnetic resonance spectroscopy to disorders such as multiple sclerosis, that continue to fall below clinically beneficial thresholds for, e.g., diagnosis.
Yavne was established in October 1948 as a transit camp for Jews from Arab countries, Iran and Europe. The first neighbourhood was established in early 1949. In the early years, the inhabitants were shopkeepers, farmers and construction workers. In 1953, the population was 1,600. In the 1960s, several enterprises moved from Tel Aviv to Yavne, establishing leather, textile, and metallurgy industries. By 1970, the population had grown to 10,100. Other Israeli villages were founded on Yibna land were Kfar HaNagid and Beit Gamliel in 1949, Ben Zakai in 1950, Kfar Aviv (originally: "Kfar HaYeor") in 1951, Tzofiyya in 1955. According to Walid Khalidi, a railroad crosses the village. The old mosque and minaret, together with a shrine can still be seen, and some of the old houses are inhabited by Jewish and Arab families. The 1980 edition of a guidebook published in Jerusalem describes Yavne as home to Israel's first atomic reactor, an image of which appeared on a 0.50 Shekel stamp. When Mayor Meir Sheetrit assumed office in 1974, the city became a low-density suburban satellite of Tel Aviv with new construction targeting middle-class families. Yavne achieved city status in 1986. By the mid-1990s, the population had risen to 25,600.
The goal of this process is to reduce the amount of material being transferred to the surface and minimize land-based. The dewatering process is a mining waste process that would most likely contribute to the formation of sediment plumes from the surface. The method of mine waste disposal releases water from the ship that may have been obtained during the extraction and transport of the material from the seafloor to the surface. The third contribution to the formation of the sediment plume or cloud would be sediment disturbance and release. This mining waste contribution is mainly associated with the mining activity on the seafloor associated with the movement of the ROVs and the destructive disturbance of the seafloor as part of the mining process itself. The two main environmental concerns as a result of these waste mining processes that contribute to the formation of the sediment plume would be the release of heavy metals and increased amounts of sediment released. The release of heavy metals is mainly associated with the dewatering process that would take place on board the ship at the surface of the water. The main problem associated with dewatering is that it is not just the release of seawater re-entering the water column. Heavy metals such as copper and cobalt that would be sourced from the material extracted on the seafloor are also mixed in with the water that is released into the water column. The first environmental concern associated with the release of heavy metals is that it has the potential to change ocean chemistry within that localized water column area.
Thank you." In January 2016, Schumer was accused of stealing jokes from comedians Tammy Pescatelli, Kathleen Madigan, Wendy Liebman, and Patrice O'Neal. Schumer denied the allegations. Other comedians, such as Marc Maron and Dave Rubin, defended Schumer. Pescatelli later apologized, stating it had "gone too far" and was probably "parallel thinking".
The disorganised basal cells are seen to be responsible for the major airway changes that are characteristic of COPD, and with continued stress can undergo a malignant transformation. Studies have shown that the initial development of emphysema is centred on the early changes in the airway epithelium of the small airways. Basal cells become further deranged in a smoker's transition to clinically defined COPD.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.